# Nong Yang

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/nong-yang/

## Facts

| Field | Value |
| --- | --- |
| Citations | 7,287 |
| Field | Lung Cancer Treatments and Mutations |
| h-index | 39 |
| i10-index | 103 |
| Last Known Institution | Central South University |
| OpenAlex ID | https://openalex.org/A5076756498 |
| ORCID iD | 0000-0003-0997-3645 |
| Works | 253 |

## Researcher papers

Showing 12 of 13.

- [Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial](https://scholariq.org/papers/durvalumab-with-or-without-tremelimumab-plus-platinum-etoposide-versus-platinum/)
- [Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Non–Small Cell Lung Cancer Patients](https://scholariq.org/papers/investigating-novel-resistance-mechanisms-to-third-generation-egfr-tyrosine/)
- [Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First-line Treatment for Advanced Squamous Non–Small-Cell Lung Cancer](https://scholariq.org/papers/tislelizumab-plus-chemotherapy-vs-chemotherapy-alone-as-first-line-treatment-for/)
- [Efficacy and Safety of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC: a Randomized, Double-Blind, Phase 3 Study (Oncology pRogram by InnovENT anti-PD-1-11)](https://scholariq.org/papers/efficacy-and-safety-of-sintilimab-plus-pemetrexed-and-platinum-as-first-line/)
- [Perioperative Toripalimab Plus Chemotherapy for Patients With Resectable Non–Small Cell Lung Cancer](https://scholariq.org/papers/perioperative-toripalimab-plus-chemotherapy-for-patients-with-resectable-non/)
- [AENEAS: A Randomized Phase III Trial of Aumolertinib Versus Gefitinib as First-Line Therapy for Locally Advanced or MetastaticNon–Small-Cell Lung Cancer With <i>EGFR</i> Exon 19 Deletion or L858R Mutations](https://scholariq.org/papers/aeneas-a-randomized-phase-iii-trial-of-aumolertinib-versus-gefitinib-as-first/)
- [Bevacizumab plus erlotinib in Chinese patients with untreated, EGFR-mutated, advanced NSCLC (ARTEMIS-CTONG1509): A multicenter phase 3 study](https://scholariq.org/papers/bevacizumab-plus-erlotinib-in-chinese-patients-with-untreated-egfr-mutated/)
- [Repotrectinib in <i>ROS1</i> Fusion–Positive Non–Small-Cell Lung Cancer](https://scholariq.org/papers/repotrectinib-in-i-ros1-i-fusion-positive-non-small-cell-lung-cancer/)
- [Once-daily savolitinib in Chinese patients with pulmonary sarcomatoid carcinomas and other non-small-cell lung cancers harbouring MET exon 14 skipping alterations: a multicentre, single-arm, open-label, phase 2 study](https://scholariq.org/papers/once-daily-savolitinib-in-chinese-patients-with-pulmonary-sarcomatoid-carcinomas/)
- [Safety, Efficacy, and Pharmacokinetics of Almonertinib (HS-10296) in Pretreated Patients With EGFR-Mutated Advanced NSCLC: A Multicenter, Open-label, Phase 1 Trial](https://scholariq.org/papers/safety-efficacy-and-pharmacokinetics-of-almonertinib-hs-10296-in-pretreated/)
- [Genomic alterations and clinical outcomes in patients with lung adenocarcinoma with transformation to small cell lung cancer after treatment with EGFR tyrosine kinase inhibitors: A multicenter retrospective study](https://scholariq.org/papers/genomic-alterations-and-clinical-outcomes-in-patients-with-lung-adenocarcinoma/)
- [Clinical impact of uncommon epidermal growth factor receptor exon 19 insertion-deletion variants on epidermal growth factor receptor-tyrosine kinase inhibitor efficacy in non-small-cell lung cancer](https://scholariq.org/papers/clinical-impact-of-uncommon-epidermal-growth-factor-receptor-exon-19-insertion/)

## Researcher topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Colorectal Cancer Treatments and Studies](https://scholariq.org/topics/colorectal-cancer-treatments-and-studies/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)

## Researcher university

- [Central South University](https://scholariq.org/institutions/central-south-university/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.